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Gustatory and Olfactory
Hallucinations Under
Therapeutic Dosing of
Bupropion
To the Editor: The antidepressant
bupropion acts via dual inhibition
of dopamine and norepinephrine
reuptake, without a serotonergic
activity.1 Various case reports exist
in the literature about psychotic
phenomena after bupropion
intake.2,3 Specifically, the literature
documents case reports of audi-
tory,2 visual,4 and tactile5 halluci-
nations. To our knowledge, this is
the first case of olfactory and gus-
tatory hallucinations in an adult
taking a low therapeutic dose of
bupropion, without any predispos-
ing factors.
Case Report
Ms. X. is a 36-year-old woman
without any psychiatric history,
including abuse of alcohol, con-
sumption of illegal drugs, or regu-
lar consumption of medication. She
reported a depressed mood that
lasted 2 weeks. She had to cry very
often, without any trigger. Further-
more, she suffered from loss of
concentration, a high sleep require-
ment, ruminations, anhedonia, and
a reduced libido. Her mother suf-
fered from a recurrent depressive
disorder, and her father was
addicted to alcohol. According to
the described pathology above, the
patient fulfilled the DSM-IV criteria
for a major depression. Because of
her emotional discomfort, anhedo-
nia, and reduction in libido, an
antidepressant pharmacotherapy
with 150 mg daily bupropion,
extended release, was launched.
Ten days later, Ms. X. reported
that, upon starting the medication
regimen, she had been overly sen-
sitive to stimuli such as noise. Fur-
thermore, she had been anxious,
had a headache, and tachycardia.
Six days after taking the bupropion
extended release she noticed gusta-
tory and olfactory hallucinations.
For example, a meal with chicken
would have tasted of liver, while
her office, as well as the waiting
room of her general practitioner,
would have smelled intensely of
her boss’s perfume, even though he
had been on vacation that week.
Orientation and concentration were
unremarkable. Delusions and disor-
ders of ego did not emerge. She
continued the medication, and,
after 2 days, the pathology disap-
peared. The bupropion level in
serum during the follow-up
appointment was 65.0 ng/ml (stan-
dard value: 50 ng/ml–450 ng/ml).
Six weeks later, at a follow-up
appointment, Ms. X. did not report
any further side effects of the med-
ication. Further diagnostic proce-
dures such as MRI were declined
by the patient.
Discussion
There are only few case reports
about hallucinations in adults after
taking bupropion in therapeutic
doses.5
Upon reviewing the published
literature, we hypothesize various
risk factors for hallucinatory symp-
toms after taking bupropion. Vul-
nerability has been described for
elderly patients and for patients
with a history of psychosis3 or
bipolar disorder.4 Bupropion acts
inter alia among the inhibition of
dopamine reuptake. This may
cause dopaminergic overdrive and
thereby cause hallucinations. Our
case demonstrates that also appar-
ently healthy adults taking a low-
dose medication may develop hal-
lucinatory phenomena as side
effects. The responsible risk factors
in this case remain unknown.
Therefore information about the
side effect of hallucination should
be considered before prescribing
bupropion.
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